ES2148173T3 - Proteinas de fusion de especificidad mixta. - Google Patents

Proteinas de fusion de especificidad mixta.

Info

Publication number
ES2148173T3
ES2148173T3 ES92906135T ES92906135T ES2148173T3 ES 2148173 T3 ES2148173 T3 ES 2148173T3 ES 92906135 T ES92906135 T ES 92906135T ES 92906135 T ES92906135 T ES 92906135T ES 2148173 T3 ES2148173 T3 ES 2148173T3
Authority
ES
Spain
Prior art keywords
fusion proteins
patient
inhibit
present
union
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906135T
Other languages
English (en)
Inventor
Alejandro A Aruffo
Peter S Linsley
Jeffery A Ledbetter
Nitin K Damle
H Perry Fell Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2148173T3 publication Critical patent/ES2148173T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTAN PROTEINAS DE FUSION DE ESPECIFICIDAD MIXTA CAPACES DE UNIRSE A MOLECULAS DE ADHESION CELULAR. LAS PROTEINAS DE FUSION CONTIENE UNA REGION DE POLIPEPTIDO, TAL COMO UNA REGION CONSTANTE IGC OPERATIVAMENTE UNIDA A AL MENOS DOS REGIONES DE UNION CADA UNA DE LAS CUALES SE CORRESPONDE CON UNA EXTENSION EXTRACELULAR CON UN RECEPTOR DE LA SUPERFICIE CELULAR PARA LAS MOLECULAS DE ADHESION CELULAR, O UNA REGION VARIABLE DE UN ANTICUERPO DIRIGIDO A UNA MOLECULA DE ADHESION CELULAR. SE PRESENTA UN METODO PARA INHIBIR LA INFLAMACION EN UN PACIENTE EN EL CUAL SE ADMINISTRAN LAS PRESENTES PROTEINAS DE FUSION AL PACIENTE PARA INHIBIR LA UNION DE CELULAS INFLAMATORIAS AL ENDOTELIO VASCULAR. SE PRESENTA UN METODO PARA INHIBIR LA METASTASIS EN EL CUAL LAS PRESENTES PROTEINAS DE FUSION SE ADMINISTRAN A UN PACIENTE PARA INHIBIR LA METASTASIS DE CELULAS TUMORALES SENSIBLES.
ES92906135T 1991-01-24 1992-01-24 Proteinas de fusion de especificidad mixta. Expired - Lifetime ES2148173T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/645,522 US5709859A (en) 1991-01-24 1991-01-24 Mixed specificity fusion proteins

Publications (1)

Publication Number Publication Date
ES2148173T3 true ES2148173T3 (es) 2000-10-16

Family

ID=24589356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906135T Expired - Lifetime ES2148173T3 (es) 1991-01-24 1992-01-24 Proteinas de fusion de especificidad mixta.

Country Status (18)

Country Link
US (1) US5709859A (es)
EP (1) EP0568645B1 (es)
JP (1) JP3394534B2 (es)
KR (1) KR100259061B1 (es)
AT (1) ATE195254T1 (es)
AU (1) AU648398B2 (es)
CA (1) CA2099779C (es)
DE (1) DE69231333T2 (es)
DK (1) DK0568645T3 (es)
ES (1) ES2148173T3 (es)
FI (1) FI109203B (es)
GR (1) GR3034524T3 (es)
IE (1) IE920202A1 (es)
IL (1) IL100731A (es)
NO (1) NO313241B1 (es)
NZ (1) NZ241357A (es)
WO (1) WO1992012994A1 (es)
ZA (1) ZA92467B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
SG48892A1 (en) * 1993-01-25 1998-05-18 Dana Faber Cancer Inst Inc Chimeric L- and P-selectin by exchange of domains-uses thereof
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999049028A1 (en) 1998-03-23 1999-09-30 Genentech, Inc. Method of selection for genes encoding secreted and transmembrane proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
WO2000058501A2 (en) * 1999-03-26 2000-10-05 The Wistar Institute Novel genetic suppressor elements and methods of making the same
BR0010725A (pt) * 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DK1200479T3 (da) * 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
DE60118362T2 (de) * 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
DK1294401T3 (da) * 2000-06-29 2007-10-08 Merck Patent Gmbh Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
AU2002356496A1 (en) * 2001-05-16 2003-04-01 Ceptyr, Inc. Dsp-18 dual-specificity phosphatase
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
RU2369616C2 (ru) 2003-12-30 2009-10-10 Мерк Патент Гмбх Слитые белки il-7
AU2004309063B2 (en) * 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005066348A2 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
CA2565872C (en) * 2004-05-11 2016-06-21 Abgenomics Corporation T-cell death-inducing epitopes
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2591297C (en) * 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
UA97469C2 (uk) * 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
NZ603059A (en) * 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
MX2011011044A (es) * 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
KR101632312B1 (ko) 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
EP2536435B1 (en) 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
US8426186B2 (en) 2010-04-16 2013-04-23 Centocor Ortho Biotech Inc. Engineered potato virus A nuclear inclusion protein
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
SG10201407036YA (en) 2010-11-05 2014-12-30 Transbio Ltd Markers of Endothelial Progenitor Cells and Uses Thereof
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2017066530A1 (en) * 2015-10-15 2017-04-20 Anthrogensis Corporation Natural killer cells and ilc3 cells and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
EP0365837B1 (en) * 1988-09-28 1995-08-02 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP0583799A1 (en) * 1989-05-23 1994-02-23 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to ELAM-1 sialoglycoprotein antigen on the surface of activated endothelial cells
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules

Also Published As

Publication number Publication date
AU648398B2 (en) 1994-04-21
EP0568645A4 (en) 1994-09-28
DE69231333D1 (de) 2000-09-14
KR100259061B1 (ko) 2000-07-01
DE69231333T2 (de) 2001-01-18
WO1992012994A1 (en) 1992-08-06
EP0568645B1 (en) 2000-08-09
AU1339192A (en) 1992-08-27
NO932437L (no) 1993-09-17
IE920202A1 (en) 1992-07-29
IL100731A0 (en) 1992-09-06
ATE195254T1 (de) 2000-08-15
JPH06505388A (ja) 1994-06-23
GR3034524T3 (en) 2000-12-29
KR930703008A (ko) 1993-11-29
FI933292A0 (fi) 1993-07-21
EP0568645A1 (en) 1993-11-10
DK0568645T3 (da) 2000-09-18
CA2099779C (en) 2002-03-19
FI933292A (fi) 1993-07-21
JP3394534B2 (ja) 2003-04-07
IL100731A (en) 1997-07-13
NZ241357A (en) 1994-04-27
NO932437D0 (no) 1993-07-05
FI109203B (fi) 2002-06-14
US5709859A (en) 1998-01-20
CA2099779A1 (en) 1992-07-25
ZA92467B (en) 1992-09-30
NO313241B1 (no) 2002-09-02

Similar Documents

Publication Publication Date Title
ES2148173T3 (es) Proteinas de fusion de especificidad mixta.
Al‐Samadi et al. IL‐17 C and its receptor IL‐17 RA/IL‐17 RE identify human oral epithelial cell as an inflammatory cell in recurrent aphthous ulcer
Smolarczyk et al. The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
TR200100149T2 (tr) Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
ES2113088T3 (es) Metodo de entrega de agentes a celulas diana.
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
ATE403680T1 (de) Herstellung tetravalenter antikörper
ATE245437T1 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
DE3885317D1 (de) Makromolekulare Platin-Antitumorverbindungen.
ATE47155T1 (de) Monoklonaler antikoerper.
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
ATE186738T1 (de) Kohlenhydratmodifizierte cytostatika
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE60142861D1 (de) Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
BR0312483A (pt) Anticorpos e seus usos
DK0837672T3 (da) Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme
DE59712847D1 (de) Monoklonaler Antikörper gegen MxA und MxB
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
DK1196188T3 (da) VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser
DK0929310T3 (da) Diagnostiske og terapeutiske metoder relateret til regulering af energimobilisering med OB-protein og OB-antistoffer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 568645

Country of ref document: ES